Sign In
Buy PRTA
$8.12
-0.290 (-3.45%)
At Close: Jul 31, 2026
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:16pm, Friday, 01'st Jul 2022 GlobeNewswire Inc.
DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics bu
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena to Participate in Jefferies Healthcare Conference
08:05pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
04:24pm, Friday, 06'th May 2022 Zacks Investment Research
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
01:33pm, Friday, 06'th May 2022
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
10:35pm, Thursday, 05'th May 2022 Zacks Investment Research
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
08:19pm, Thursday, 05'th May 2022
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock
07:44pm, Monday, 02'nd May 2022 Benzinga
RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in
Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock
03:49pm, Monday, 02'nd May 2022
RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in
10 Biggest Price Target Changes For Monday
12:36pm, Monday, 02'nd May 2022 Benzinga
Morgan Stanley boosted Archer-Daniels-Midland Company (NYSE: ADM) price target from $69 to $94. Archer-Daniels-Midland shares fell 0.5% to $89.10 in pre-market trading.
RBC Capital cut the price tar
Prothena (PRTA) IND Application Gets FDA Clearance for AD
03:44pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Prothena (PRTA) IND Application Gets FDA Clearance for AD
12:48pm, Tuesday, 29'th Mar 2022
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
12:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protei
Prothena to Participate in Stifel 2022 Virtual CNS Days
08:05pm, Monday, 21'st Mar 2022 GlobeNewswire Inc.
DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built
